0001193125-26-211951
SEC filingQ1 operating losses widened modestly to -$59.8M from -$59.1M amid intensified Phase 3 clinical investments, partially offset by manufacturing efficiencies and facilities cost reductions, highlighting ongoing cash burn in late-stage retinal development.
Kodiak Sciences reported a GAAP operating loss of -$59.8 million for Q1 2026, widening 1.2% from -$59.1 million in the prior year. This reflects the company's focus on advancing late-stage retinal programs, where clinical investments outpaced certain cost efficiencies. Net income followed suit at -$58.2 million versus -$57.5 million YoY, with diluted EPS improving to -$0.94 from -$1.09—a 13.8% per-share gain attributable to stable share count amid ongoing equity funding.
Management's discussion highlights program-specific dynamics in Item 2. KSI-101 expenses increased due to elevated costs for the PEAK/PINNACLE Phase 3 trials, driving overall R&D pressure as Kodiak pushes toward potential BLA submissions. Offsetting this, tarcocimab program costs declined on reduced manufacturing expenses, demonstrating supply chain optimization. Facilities and other R&D expenses also fell following the early 2025 sublease of a corporate office building, which lowered allocated rent—illustrating proactive cost management in a high-burn environment.